Jason Throne is CLO at IDEAYA Biosciences, Inc. (IDYA). They have made 2 open-market trades across 1 company since 2020, most recently 2024-06-27.
CIK 0001790865
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| IDYA | 16,424 | $539K |
Shares reported on the most recent Form 4, priced at the 2024-06-27 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IDYA | SELL · 10b5-1 | 2023-12-15 | 2023-12-19 | $35.04 | $350K | +1.9% | +20.1% | +25.8% |
| IDYA | SELL · 10b5-1 | 2023-11-03 | 2023-11-07 | $30.09 | $311K | +3.2% | +6.3% | +48.2% |
| IDYA | SELL · 10b5-1 | 2023-09-12 | 2023-09-14 | $30.01 | $30K | -10.9% | -17.1% | +10.6% |
| IDYA | SELL · 10b5-1 | 2023-09-01 | 2023-09-06 | $30.03 | $167K | +1.7% | -6.0% | +10.8% |
| IDYA | SELL · 10b5-1 | 2023-08-09 | 2023-08-11 | $25.09 | $125K | +12.3% | +15.7% | +17.4% |
| IDYA | SELL · 10b5-1 | 2023-07-10 | 2023-07-12 | $23.00 | $218K | -4.0% | +10.9% | +18.9% |
| IDYA | SELL · 10b5-1 | 2023-05-31 | 2023-06-02 | $23.02 | $174K | +0.5% | -7.4% | +18.8% |
| IDYA | SELL · 10b5-1 | 2023-05-22 | 2023-05-24 | $23.00 | $12K | +8.6% | +8.8% | +24.2% |
| IDYA | SELL | 2021-07-27 | 2021-07-29 | $25.17 | $503K | -2.2% | -2.0% | -7.6% |
| IDYA | SELL | 2021-07-06 | 2021-07-08 | $22.21 | $366K | +17.9% | +34.0% | +49.3% |
| IDYA | SELL · 10b5-1 | 2020-12-04 | 2020-12-08 | $15.37 | $30K | -26.4% | -19.8% | +20.2% |
| IDYA | SELL · 10b5-1 | 2020-06-04 | 2020-06-08 | $8.66 | $19K | +59.1% | +53.9% | +35.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.